~~WHAT IS CLAIMED IS:~~

1. ~~A pharmaceutical composition comprising a~~ Use of a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for alleviating a side effect of treatment with solifenacin in a patient; wherein the patient is to be administered with the pilocarpine, or a pharmaceutically acceptable salt thereof, about 2 hours after the solifenacin, or its pharmaceutically acceptable salt thereof has been administered.

~~2. The composition of claim 1, wherein solifenacin, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, are together disposed in the same dosage form.~~

32. The ~~composition~~use of claim 1, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

43. The ~~composition~~use of claim 1, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, or 20 mg.

54. The ~~composition~~use of claim 1, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

65. The ~~composition~~use of claim 1, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, or 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 10.5 mg, 11 mg, 11.5 mg, 12 mg, 13 mg, and 15 mg.

~~7. The composition of claim 1, further comprising a pharmaceutically acceptable carrier, diluent, or excipient.~~

~~8. Use of a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a patient suffering from overactive bladder.~~

~~9. The use of claim 8, wherein solifenacin, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, are together disposed in the same dosage form.~~

~~10. The use of claim 8, wherein solifenacin, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, are administered separately.~~

~~11. The use of claim 8, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.~~

~~12. The use of claim 8, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 10 mg, 12 mg, 14 mg, 15 mg, 16 mg, or 20 mg.~~

~~13. The use of claim 8, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.~~

~~14. The use of claim 8, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, or 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 10.5 mg, 11 mg, 11.5 mg, 12 mg, 13 mg, and 15 mg.~~

156. Use of a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for alleviating a dry mouth side effect of treatment ~~for overactive bladder~~with solifenacin in a patient; ~~suffering therefrom~~wherein the patient is to be administered with the pilocarpine, or a pharmaceutically acceptable salt thereof, about 2 hours after the solifenacin, or a pharmaceutically acceptable salt thereof, has been administered.

~~16. The use of claim 15, wherein solifenacin, or a pharmaceutically acceptable salt thereof, and pilocarpine, or a pharmaceutically acceptable salt thereof, are together disposed in the same dosage form.~~

177. The use of claim 156, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

188. The use of claim 156, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 10 mg, 12 mg, 14 mg, 15 mg, 16 mg, or 20 mg.

199. The use of claim 156, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

2010. The use of claim 156, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 4.5 mg, 5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8.mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 10.5 mg, 11 mg, 11.5 mg, 12 mg, 13 mg, and 15 mg.

11. The use of claim 1, wherein the side effect is selected from the group consisting of dry mouth, discomfort around the mouth, difficulty speaking secondary to dry mouth, difficulty chewing food secondary to dry mouth, and lack of quality of sleep.

12. The use of claim 1, wherein the side effect is dry mouth.

WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of overactive bladder in a patient; wherein the patient is to be administered with the pilocarpine, or a pharmaceutically acceptable salt thereof, about 2 hours after the solifenacin, or its pharmaceutically acceptable salt thereof has been administered.

2. The use of claim 1, wherein the medicament is capable of alleviating an adverse symptom secondary to dry mouth resulting from treatment with solifenacin.

3. The use of claim 2, wherein the adverse symptom secondary to dry mouth is selected from the group consisting of discomfort around the mouth, difficulty speaking, difficulty chewing food, and lack of quality of sleep.

4. The use of any of claims 1-3, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

5. The use of any of claims 1-3, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, or 20 mg.

6. The use of any of claims 1-3, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

7. The use of any of claims 1-3, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, or 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 10.5 mg, 11 mg, 11.5 mg, 12 mg, 13 mg, and 15 mg.

8. Use of a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for alleviating a dry mouth side effect of treatment with solifenacin in a patient; wherein the patient is to be administered with the pilocarpine, or a pharmaceutically acceptable salt thereof, about 2 hours after the solifenacin, or a pharmaceutically acceptable salt thereof, has been administered.

9. The use of claim 8, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

10. The use of claim 8, wherein solifenacin, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 10 mg, 12 mg, 14 mg, 15 mg, 16 mg, or 20 mg.

11. The use of claim 8, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose of between 0.1 mg to 50 mg.

12. The use of claim 8, wherein pilocarpine, or a pharmaceutically acceptable salt thereof, is present in a dose selected from the group consisting of 1 mg, 2 mg, 3 mg, 4 mg, 4.5 mg, 5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 10.5 mg, 11 mg, 11.5 mg, 12 mg, 13 mg, and 15 mg.